Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Nanoviricides? Wasn’t he CFO or Co Founder of that gem?"

The IPIX CEO was an original Officer who held the position of CFO of Nanoviricides from 2005 to 2007.
At the time of that Company's initial SEC filing, signed by him on 11/14/2006, he and 5 of his family members held shares.
He also held (holds?) shares in a private company called Theracour which in turn was and is a majority shareholder in NNVC.

That's a rabbit hole.

My only reason for mentioning NNVC at this point was to note that that Company was talking about developing treatments for Ebola, Marburg and West Nile viruses (which never saw a clinical trial, btw) while Ehrlich was CFO and now those same viruses have popped up as targets for IPIX research. People can decide for themselves whether that is at all meaningful.

https://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_10sb.htm



(In that same filing IPIX's former Officer and Director, Krishna Menon, was identified as NNVC's Chief Regulatory Officer and a shareholder....and in other ways:
"Prior thereto and from 1988 to 1997, Dr. Menon was the In Vivo Scientist of Dana-Farber Cancer Institute"
"Dr. Menon also serves on the board of directors of KARD Scientific, MA, and Biological Supplies, NY, and scientific advisor to Nexus Pharmaceuticals. He participated in the development of 8 International and 3 US patents. Dr. Menon received a PhD from Harvard. While at Harvard, he performed pre-clinical studies on AZT, an important anti-HIV drug. Dr. Menon is a member of the drug development advisory board for various faculties at Harvard.)



ps. Hungry Ghost just offered this:
"IMO you can definitely add HIV, HERPES as enveloped viruses being involved in the testing"
Guess who else has tried to do that? In fact NNVC was on the verge of submitting an IND for shingles (a herpes virus) when they too were distracted by the coronavirus.

People will note that there is a big difference between CTIX/IPIX and NNVC in that the latter has never conducted a clinical trial. The thing that they have in common is a pattern of abandoning their development efforts and a failure to follow through. And yet, they both continue to raise money and pay their officers.